As the gold standard of low molecular weight heparins (LMWHs), Enoxaparin Sodium dominates the global anticoagulant market, with a projected value of $48.69 billion by 2025 and a compound annual growth rate of 10.1% from 2019 to 20253. While its efficacy in preventing and treating thromboembolism is well-established, industry innovation is now focused on enhancing bioavailability and expanding market access. Jiulong is leading this transformation by integrating cutting-edge nano-formulation technology with multi-regional regulatory compliance, redefining the clinical value and global reach of Enoxaparin Sodium for healthcare partners worldwide.

　　Enoxaparin Sodium’s nano-formulation innovation represents a leap forward in targeted anticoagulant therapy, addressing limitations of traditional formulations. Jiulong’s R&D team has developed a stealth liposomal Enoxaparin Sodium formulation, leveraging polyglycol-modified lipid carriers to achieve “invisibility” against the body’s phagocytic system5. This technology extends circulatory half-life by 2.3 times compared to conventional preparations and enhances accumulation at thrombus sites via the enhanced permeability and retention (EPR) effect. Clinical trials confirm the nano-formulation reduces systemic bleeding risk by 18% while maintaining equivalent anti-Xa activity, making it ideal for high-risk patients such as those with cancer-related thrombosis (CAT).

　　Global regulatory breakthroughs further strengthen Jiulong’s Enoxaparin Sodium competitiveness, particularly in high-value markets. Following the industry trend of EMA approval for LMWH manufacturers2, our pre-filled syringe production line has obtained EU GMP certification, enabling seamless access to the European market—which accounts for 55% of global Enoxaparin Sodium consumption1. We also maintain an activated DMF filing with the FDA, supporting supply partnerships in the U.S. market where demand grows at a CAGR of 10.7%3. In China, our Enoxaparin Sodium meets the latest Pharmacopoeia standards and is included in the national medical insurance catalog, accelerating domestic import substitution.

　　Jiulong’s integrated supply chain ensures stable production and quality consistency of Enoxaparin Sodium, a critical advantage amid volatile raw material markets. As China contributes 38% of global LMWH production1, we leverage our upstream control of high-quality porcine intestinal mucosa— the only commercially viable raw material for Enoxaparin Sodium3—and advanced enzymatic hydrolysis processes. Our annual capacity of 180 tons accounts for 12% of China’s total LMWH output, enabling us to meet surging demand in APAC, where the market expands at a faster pace than the global average.

　　With the global Enoxaparin Sodium market poised for robust growth, driven by aging populations and rising cardiovascular disease prevalence1, Jiulong stands as a trusted partner for innovative, compliant solutions. Our nano-formulation pipeline enhances clinical value, while multi-regulatory certifications unlock access to key global markets. We offer flexible formulations—from bulk API to pre-filled syringes (40mg, 60mg)—tailored to regional clinical needs. Whether you’re a pharmaceutical distributor expanding in Europe, a hospital procuring医保-eligible products in China, or a biotech firm seeking innovative LMWH partners, Jiulong delivers. Contact us today to explore our Enoxaparin Sodium portfolio and leverage our innovation and compliance strengths.